| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | निपटाया (D) | 1,48,153 | 11.00 | 16,29,683 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 1629683.00। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) व्युत्पन्न प्रतिभूति: Prefunded Warrants — अंतर्निहित Common Stock (4,33,962) — प्रयोग मूल्य 0.0001 | निपटाया (D) | 4,33,962 | 10.999 | 47,73,148.038 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 4773148.038। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) व्युत्पन्न प्रतिभूति: Series A Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,17,019) — प्रयोग मूल्य 8.16 | निपटाया (D) | 1,17,019 | 4.71 | 5,51,159.49 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 551159.49। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) व्युत्पन्न प्रतिभूति: Series C Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,17,019) — प्रयोग मूल्य 8.16 | निपटाया (D) | 1,17,019 | 4.71 | 5,51,159.49 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 551159.49। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) व्युत्पन्न प्रतिभूति: Amended Series A Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,58,531) — प्रयोग मूल्य 0.01 | निपटाया (D) | 1,58,531 | 10.99 | 17,42,255.69 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 1742255.69। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 19 दिस॰ 2025 को दाखिल | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) व्युत्पन्न प्रतिभूति: Amended Series C Common Stock Purchase Warrants — अंतर्निहित Common Stock (2,50,627) — प्रयोग मूल्य 0.01 | निपटाया (D) | 2,50,627 | 10.99 | 27,54,390.73 व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 2754390.73। | 0 | अप्रत्यक्ष (I) See Footnote | नहीं | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 5.41 | निपटाया (D) | 1,218 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,218 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,479) — प्रयोग मूल्य 5.41 | निपटाया (D) | 1,479 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (8,750) — प्रयोग मूल्य 4.45 | निपटाया (D) | 8,750 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,291) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,291 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 5.41 | निपटाया (D) | 1,187 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,187 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,250) — प्रयोग मूल्य 5.41 | निपटाया (D) | 1,250 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,250) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,250 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 5.41 | निपटाया (D) | 1,218 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,187 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 5.51 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322645 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,125) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,125 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322645 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (17,291) — प्रयोग मूल्य 5.27 | निपटाया (D) | 17,291 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (11,000) — प्रयोग मूल्य 4.45 | निपटाया (D) | 11,000 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (64,840) — प्रयोग मूल्य 5.27 | निपटाया (D) | 64,840 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (70,000) — प्रयोग मूल्य 4.45 | निपटाया (D) | 70,000 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (17,291) — प्रयोग मूल्य 5.27 | निपटाया (D) | 17,291 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (13,000) — प्रयोग मूल्य 4.45 | निपटाया (D) | 13,000 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 5.26 | निपटाया (D) | 5,833 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322646 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 17 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,155) — प्रयोग मूल्य 3.453 | निपटाया (D) | 1,155 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| फ़ाइलिंग खोलें 0001193125-25-322646 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 133 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 2,330 | — | — | 0 | अप्रत्यक्ष (I) By Garner Investments, L.L.C. | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 27 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 360 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 15,509 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |
| 16 दिस॰ 2025 17 दिस॰ 2025 को दाखिल | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | निपटाया (D) | 11,815 | — | — | 0 | प्रत्यक्ष (D) | नहीं | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें |